THE USE OF EMPAGLYFLOSINE IN PATIENTS WITH CHRONIC CARDIAC FAILURE AND DYSFUNCTION OF THE KIDNEYS

Khudoyberdiyeva G.A; Raimkulova N.R.

doi:10.61796/jmgcb.v2i12.1477

Authors

Khudoyberdiyeva G.A
Khudoy@gamil.com
Tashkent State Medical University, Uzbekistan
Raimkulova N.R. Republican Specialized Scientific and Practical Medical Center of Nephrology and Kidney Transplantation, Uzbekistan

Vol. 2 No. 12 (2025): Journal of Medical Genetics and Clinical Biology

Articles

October 10, 2025

Downloads

View Article

Abstract
How to Cite
Metrics
References
License

Objective: This study aimed to evaluate the effects of empagliflozin on carbohydrate metabolism and lipid profile in patients with chronic heart failure and kidney dysfunction. Method: A total of 54 patients were enrolled and received empagliflozin therapy for six months. Clinical parameters, including fasting glucose, glycated hemoglobin (HbA1c), insulin levels, total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides, and glomerular filtration rate (GFR), were measured before and after treatment to assess metabolic and renal outcomes. Results: The findings demonstrated significant reductions in glucose, HbA1c, insulin, total cholesterol, LDL, and triglycerides, alongside an increase in HDL levels, while GFR remained stable throughout the treatment period. These outcomes suggest favorable metabolic modulation without deterioration of renal function. Novelty: This study provides novel clinical evidence supporting the dual cardiometabolic benefits of empagliflozin in patients with concurrent heart failure and renal impairment, emphasizing its therapeutic potential beyond glycemic control in improving overall metabolic health and cardiovascular protection.

G.A, K., & N.R. , R. (2025). THE USE OF EMPAGLYFLOSINE IN PATIENTS WITH CHRONIC CARDIAC FAILURE AND DYSFUNCTION OF THE KIDNEYS. Journal of Medical Genetics and Clinical Biology, 2(12), 602–606. https://doi.org/10.61796/jmgcb.v2i12.1477

Download Citation

G. L. Bakris, R. Agarwal, S. D. Anker, B. Pitt, L. M. Ruilope, P. Rossing, et al., “Effect of finerenone on the outcome of chronic kidney disease in type 2 diabetes,” N. Engl. J. Med., vol. 385, no. 24, pp. 2252–2263, 2021, doi: 10.1056/NEJMoa2110956.

D. L. Bhatt, et al., “Sotagliflozin reduces heart failure events in patients with diabetes and CKD regardless of albuminuria status,” J. Am. Coll. Cardiol., vol. 78, no. 1, pp. 101–110, 2021.

M. E. Cooper, et al., “The interplay between diabetes, heart failure, and chronic kidney disease: Mechanisms and therapeutic implications,” Diabetologia, vol. 64, no. 2, pp. 271–281, 2021.

G. Filippatos, S. D. Anker, M. Böhm, et al., “Benefits of Finerenone to improve outcomes in patients with kidney disease diabetes,” J. Am. Coll. Cardiol., vol. 79, no. 12, pp. 1508–1518, 2022.

H. J. L. Heerspink, et al., “Justification and design of the EMPA-KIDNEY study,” Clin. J. Am. Soc. Nephrol., vol. 16, no. 1, pp. 124–136, 2021.

M. J. Jardine, et al., “The role of finerenone in cardiorenal protection,” Lancet Diabetes Endocrinol., vol. 9, no. 7, pp. 649–659, 2021.

C. D. Kemp and J. V. Conte, “The pathophysiology of heart failure,” Cardiovasc. Pathol., vol. 30, no. 2, pp. 79–89, 2021.

J. J. V. McMurray, S. D. Solomon, S. E. Inzucchi, et al., “Cardiovascular and renal outcomes with empagliflozin in heart failure,” N. Engl. J. Med., vol. 385, no. 16, pp. 1451–1461, 2021.

V. Perkovic, et al., “Cardiorenal outcomes with finerenone in patients with CKD and T2D,” N. Engl. J. Med., vol. 385, pp. 2252–2263, 2021.

B. Pitt, L. Kober, P. Ponikowski, M. Gheorghiade, G. Filippatos, N. Greenlaw, et al., “Safety and tolerance of spironolactone in patients with heart failure and preserved ejection fraction: The TOPCAT trial,” JAMA Cardiol., vol. 5, no. 6, pp. 1–9, 2020, doi: 10.1001/jamacardio.2020.0505.

B. Pitt, et al., “The role of SGLT2 inhibitors in reducing cardiovascular and renal events in patients with chronic kidney disease,” Am. J. Cardiol., vol. 136, pp. 122–130, 2021.

SwedeHF Investigators, “Prevalence and prognostic impact of kidney disease on heart failure patients,” Open Heart, vol. 7, no. 2, 2022.

M. C. Thomas, M. E. Cooper, and P. Zimmet, “Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease,” Nat. Rev. Nephrol., vol. 17, no. 4, pp. 220–232, 2021.

S. Verma, et al., “DAPA-HF trial: Effectiveness of dapagliflozin in heart failure patients with and without diabetes,” Circulation, vol. 143, no. 13, pp. 2143–2153, 2021.

D. C. Wheeler, et al., “Effects of dapagliflozin on cardiovascular and renal outcomes in patients with CKD,” Eur. Heart J., vol. 42, no. 13, pp. 1213–1222, 2021.